1 |
李冀, 丁莹, 王呈祥, 等. 浅谈心肌缺血再灌注损伤的中医新进展[J]. 中医药学报, 2016, 44(2): 105-107.
doi: 10.19664/j.cnki.1002-2392.2016.02.035
|
2 |
刘瑞,刘璐,郭鹏.心肌缺血再灌注损伤的发病机制及其防治策略[J].世界最新医学信息文摘,2019,19(6):73-74.
doi: 10.19613/j.cnki.1671-3141.2019.06.034
|
3 |
刘斌, 陈颖. 关于太子参的研究概述[J]. 武夷科学, 2003, 19(1): 172-175.
doi: 10.3969/j.issn.1001-4276.2003.01.038
|
4 |
国家药典委员会. 中华人民共和国药典2015年版二部 [M]. 北京: 中国医药科技出版社, 2015: 929.
|
5 |
孙弼, 宛蕾, 林晓坚,等. 太子参多糖对缺血再灌注损伤模型大鼠心肌细胞凋亡的抑制作用研究[J].中国药房,2018,29(16):2175-2179.
doi: 10.6039/j.issn.1001-0408.2018.16.04
|
6 |
WANG Z, LIAO S G, HE Y, et al. Protective effects of fractions from Pseudostellaria heterophylla against cobalt chloride-induced hypoxic injury in H9c2 cell[J]. Journal of Ethnopharmacology, 2013, 147(2): 540-545.
doi: 10.1016/j.jep.2013.03.053
|
7 |
马清林, 杜丽东, 臧凯宏,等. 网络药理学在复方中药研究中的应用及其存在的问题[J].中国当代医药,2019,26(26):21-24.
|
8 |
林少兵. 太子参环肽B促血管生成作用机制研究[D]. 福州:福建医科大学,2019.DOI: 10.27020/d.cnki.gfjyu.2019.000032.
|
9 |
黄欣玮, 赵桂峰, 毛静远. 中药复方防治心肌缺血再灌注损伤机制的研究进展[J]. 中西医结合心脑血管病杂志, 2016, 14(23): 2773-2776.
doi: 10.3969/j.issn.1672-1349.2016.23.016
|
10 |
张璐.张氏医通[M].北京:人民卫生出版社,2006.
|
11 |
张东, 金艳. 对心肌再灌注损伤的中医病机的探讨[J]. 内蒙古中医药, 2003, 22(5): 1-2.
doi: 10.16040/j .cnki .cn15 -1101.2003.05.002
|
12 |
朱文叶, 王肖龙, 高俊杰, 等. 中医药在防治急性心肌缺血/再灌注损伤中的研究进展[J]. 中国医药导报, 2015, 12(29): 31-34.
|
13 |
陈婷, 黄斌, 杨超,等. 太子参现代研究进展[J].山东化工,2019,48(16):69-70.
doi: 10.19319/j.cnki.issn.1008-021x.2019.16.030
|
14 |
王伯东. 张景凤治疗胸痹气阴两虚证经验[J]. 中医文献杂志, 2010, 28(2): 42-43.
|
15 |
吴灵群. 太子参水提物(TZSW)抗大鼠心肌缺血作用及机制研究[D]. 福州: 福建医科大学, 2016.
|
16 |
KHANRA R, DEWANJEE S, K DUA T, et al. Abroma augusta L. (Malvaceae) leaf extract attenuates diabetes induced nephropathy and cardiomyopathy via inhibition of oxidative stress and inflammatory response[J]. Journal of Translational Medicine, 2015, 13(1): 6.
doi: 10.1186/s12967-014-0364-1
|
17 |
邹小艳, 范香成, 田友清,等. 木樨草素等抗心肌缺血/再灌注损伤及抑制脂代谢和细胞凋亡作用研究[J].南京中医药大学学报,2020,36(3):380-386.
doi: 10.14148/j.issn.1672-0482.2020.0380
|
18 |
严宁, 杨春霞, 马娟, 等. β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J]. 心血管病学进展, 2020, 41(3): 321-325.
doi: 10.16806/j.cnki.issn.1004-3934.2020.03.026
|
19 |
CHANG W, WU Q Q, XIAO Y, et al. Acacetin protects against cardiac remodeling after myocardial infarction by mediating MAPK and PI3K/Akt signal pathway[J]. Journal of Pharmacological Sciences, 2017, 135(4): 156-163.
doi: 10.1016/j.jphs.2017.11.009
|
20 |
YU Q, LI X, CAO X. Linarin could protect myocardial tissue from the injury of Ischemia-reperfusion through activating Nrf-2[J]. Biomedicine & Pharmacotherapy, 2017, 90: 1-7.
doi: 10.1016/j.biopha.2017.03.025
|
21 |
FIORANELLI M, BOTTACCIOLI A G, BOTTACCIOLI F, et al. Stress and inflammation in coronary artery disease: a review psychoneuroendocrineimmunology-based[J]. Frontiers in Immunology, 2018, 9: 2031.
doi: 10.3389/fimmu.2018.02031
|
22 |
ZHANG J J, PENG K, ZHANG J, et al. Dexmedetomidine preconditioning may attenuate myocardial ischemia/reperfusion injury by down-regulating the HMGB1-TLR4-MyD88-NF-кB signaling pathway[J]. PLoS One, 2017, 12(2): e0172006.
doi: 10.1371/journal.pone.0172006
|
23 |
KOEPPEN M, LEE J W, SEO S W, et al. Hypoxia-inducible factor 2-alpha-dependent induction of amphiregulin dampens myocardial ischemia-reperfusion injury[J]. Nature Communications, 2018, 9(1): 816.
doi: 10.1038/s41467-018-03105-2
|
24 |
GONALVES I F, ACAR E, COSTANTINO S, et al. Epigenetic modulation of tenascin C in the heart: Implications on myocardial ischemia, hypertrophy and metabolism[J]. Journal of Hypertension, 2019, 37(9): 1861-1870.
doi: 10.1097/HJH.0000000000002097
|